700亿，东莞出了个新首富

Core Viewpoint - The article discusses the generational transition of control within Dongyangguang, highlighting the transfer of ownership from founder Guo Meilan to her son Zhang Yushuang, marking a significant moment in the evolution of private enterprises in China [5][9][10]. Group 1: Succession of Control - Guo Meilan transferred her entire stake in two key companies to her son Zhang Yushuang, making him the sole actual controller of Dongyangguang, which has a market value of nearly 70 billion yuan [5][9]. - The transfer was a no-cost internal family gift, avoiding complex tax structures and clarifying Zhang's authority as the sole controller [11]. - This transition reflects a modern governance structure, prioritizing corporate strategy over family sentiment, and signifies a shift in leadership to a younger generation [11][12]. Group 2: Company Growth and Strategy - Dongyangguang began as a small aluminum foil processing factory in the 1990s and has evolved into a comprehensive industrial group spanning electronic materials, new energy batteries, and biomedicine [14][15]. - The company has shown remarkable strategic determination and cross-industry integration, entering the pharmaceutical sector in 2007 and the new energy sector in 2015, with significant investments in high-value materials [15][16]. - Dongyangguang's unique "technology + capital" dual-drive model has enabled it to maintain over 5% of annual revenue for R&D, resulting in over 2,000 patents and substantial capital raising exceeding 20 billion yuan [15][16]. Group 3: Future Vision under New Leadership - Zhang Yushuang aims to establish Dongyangguang as a leader in the new energy materials sector, with plans for a zero-carbon factory and significant R&D investments [19][20]. - The company is shifting focus from generic drug production to innovative drug development, with a commitment of at least 5 billion yuan for clinical research in the next five years [20]. - Zhang's strategy includes global expansion, establishing overseas production bases, and collaborating with international biotech firms to enhance the company's global footprint [20][21].